Drug Trial Radar · NCT05683418
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
241
Planned (sponsor's estimate)
Start
Feb 15, 2023
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Totus MedicinesIndustry
- Sponsor type
- Industry
- First posted
- Jan 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and efficacy of TOS-358 in women with HR+ HER2- metastatic breast cancer whose tumors have a mutation in PIK3CA and who meet all other study enrollment criteria. The main questions it aims to answer are: 1. Phase 1a: what is the maximum tolerated dose and recommended dose for phase 2? 2. Phase 1a: how safe and tolerable is TOS-358 at different dose levels when taken orally once or twice per day? 3. Phase 1b: how safe and effective is TOS-358 when given with standard of care medicines for HR+HER2- metastatic breast cancer (fulvestrant and CDK4/6i)
Conditions
- HR+/HER2-negative Breast Cancer
Interventions
TOS-358Drug
Covalent Phosphoinositide-3-Kinase (PI3K)-alpha Inhibitor
FulvestrantDrug
Intramuscular SERD at standard doses
PalbociclibDrug
CDK4/6 inhibitor at standard doses
RibociclibDrug
CDK4/6 inhibitor at standard doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Determine the rate of dose-limiting toxicities (DLTs)Time frame: First 21 days of treatment
- Incidence and severity of adverse events (AEs) and specific laboratory abnormalities graded according to NCI CTCAE v5Time frame: Start of treatment to 30 days after last dose
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
University of Southern California Cancer Center
Los Angeles, California · Recruiting
University of California San Francisco Helen Diller Family Comprehensive Cancer Center
San Francisco, California · Not yet recruiting
Florida Cancer Specialists & Research Institute
St. Petersburg, Florida · Not yet recruiting
Northwestern Memorial Hospital
Chicago, Illinois · Recruiting
Maryland Oncology Hematology Cancer Specialists
Calverton, Maryland · Recruiting
Beth Israel Deaconess Medical Center
Boston, Massachusetts · Terminated
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada · Terminated
Compass Oncology West Cancer Center
Tigard, Oregon · Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania · Terminated
Sarah Cannon Cancer Center
Nashville, Tennessee · Recruiting
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee · Recruiting
Texas Oncology - Flower Mound
Flower Mound, Texas · Recruiting
MD Anderson Cancer Center
Houston, Texas · Not yet recruiting
Virginia Cancer Specialists
Fairfax, Virginia · Terminated
Blue Ridge Cancer Care
Roanoke, Virginia · Recruiting
NEXT Oncology - Hospital Quironsalud Barcelona - PPDS
Barcelona, Spain · Recruiting
START Barcelona HM Nou Delfos
Barcelona, Spain · Recruiting
Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
Barcelona, Spain · Recruiting
Hospital Clinico San Carlos
Madrid, Spain · Recruiting
START MADRID Hospital Universitario Fundacion Jimenez Diaz - EDOS
Madrid, Spain · Terminated
START MADRID Hospital Universitario HM Sanchinarro - CIOCC
Madrid, Spain · Recruiting
Clinica Universidad de Navarra
Pamplona, Spain · Terminated
NEXT Oncology - Hospital Quironsalud Madrid - PPDS
Pozuelo de Alarcón, Spain · Terminated
Hospital Clinico Universitario de Valencia
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.